Highlights•Few classes of antifungal drugs currently exist to treat fungal infections.•Infections
caused by Candida biofilms can be resistant to known antifungal drugs.•Growth in the …

The development of antimicrobial drug resistance among pathogenic bacteria and fungi is
one of the most significant health issues of the 21st century. Recently, advances in …

The high rates of morbidity and mortality caused by fungal infections are associated with the
current limited antifungal arsenal and the high toxicity of the compounds. Additionally …

Fungal infections, such as candidiasis caused by Candida, pose a problem of growing
medical concern. In developed countries, the incidence of Candida infections is increasing …

The genus Candida includes about 200 different species, but only a few species are human
opportunistic pathogens and cause infections when the host becomes debilitated or …

Invasive candidiasis (IC) is a leading cause of mycosis-associated mortality in the United
States. We examined data from the National Center for Health Statistics and reviewed recent …

Despite improvement of antifungal therapies over the last 30 years, the phenomenon of
antifungal resistance is still of major concern in clinical practice. In the last 10 years the …

Candida commonly adheres to implanted medical devices, growing as a resilient biofilm
capable of withstanding extraordinarily high antifungal concentrations. As currently available …

Invasive fungal infections constitute a serious threat to an ever-growing population of
immunocompromised individuals and other individuals at risk. Traditional diagnostic …

Invasive fungal diseases (IFDs) present an increasing global burden in
immunocompromised and other seriously ill populations, including those caused by …